CSIMarket
 
Ascendis Pharma A  (ASND)
Other Ticker:  
 
 
Price: $148.7000 $-1.19 -0.794%
Day's High: $152.06 Week Perf: 0.36 %
Day's Low: $ 147.45 30 Day Perf: 1.43 %
Volume (M): 385 52 Wk High: $ 161.00
Volume (M$): $ 57,175 52 Wk Avg: $104.14
Open: $152.06 52 Wk Low: $64.33



 Market Capitalization (Millions $) 8,338
 Shares Outstanding (Millions) 56
 Employees -
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -653
 Cash Flow (TTM) (Millions $) 500
 Capital Exp. (TTM) (Millions $) 16

Ascendis Pharma A
Ascendis Pharma A is a biopharmaceutical company that specializes in developing innovative therapies for rare endocrine diseases. The company is focused on utilizing its proprietary TransCon technology platform to create long-acting prodrug therapies. These therapies aim to improve patients' lives by providing sustained release and targeted treatment options, reducing the burden of frequent dosing and improving efficacy. Ascendis Pharma is known for its strong pipeline of product candidates, including treatments for conditions such as growth hormone deficiency, adult growth hormone deficiency, hypoparathyroidism, and others. The company is committed to advancing scientific research and delivering transformative therapies to patients in need.


   Company Address: Tuborg Boulevard 12 Hellerup 0
   Company Phone Number: 70 22 22 44   Stock Exchange / Ticker: NASDAQ ASND
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Ascendis Pharma Unveils YORVIPATH for Chronic Hypoparathyroidism, Evolving Treatment for Patients in Germany and Austria

Published Wed, Jan 31 2024 9:01 PM UTC

Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismCOPENHAGEN, Denmark - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company specializing in the development of innovative therapies, has recently announced the commercial launch of its second TransCon product, YORVIPATH (palopegter...

Product Service News

Ascendis Pharma's Vision 2030: Propelling Healthcare Beyond Boundaries

Published Sun, Jan 7 2024 10:45 PM UTC

In a groundbreaking announcement, Ascendis Pharma A/S unveiled its strategic roadmap, Vision 2030, at the prestigious 42nd Annual J.P. Morgan Healthcare Conference. The Danish biopharmaceutical company, listed on Nasdaq under the symbol ASND, outlined its corporate milestones for 2024 while providing a glimpse into its far-reaching aspirations. This article delves into the k...

Clinical Study

Hope on the Horizon: Revolutionary Treatment for Achondroplasia Shows Remarkable Improvements in Children's Health and Quality of Life

Published Wed, Dec 20 2023 1:30 PM UTC

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100g/kg/weekCOPENHAGEN, Denmark, Dec. 20, 2023 - Ascendis Pharma A/S (Nasdaq:ASND), a leading biopharmaceutical company, has recently announced a series of groundbreaking findings from their Phase 2 clinical trial, ACcomplisH,...

Clinical Study

Revolutionizing Growth Hormone Deficiency Treatment: TransCon hGH Triumphs Over Placebo and Competitors with Unprecedented Efficacy and Unmatched Revenue Growth

Published Tue, Dec 19 2023 1:30 PM UTC



Recently, groundbreaking results from the Phase 3 foresiGHt trial have shed light on the incredible potential of TransCon hGH (lonapegsomatropin), an innovative treatment for adults suffering from growth hormone deficiency. As the world grapples with the challenges of hormonal imbalances, TransCon hGH has emerged as a beacon of hope, soaring above the competition a...

Partnership

Ascendis Pharma & Teijin Limited: Pioneering Transformative Therapies in Japan

Published Wed, Nov 29 2023 9:31 AM UTC

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan: Teijin to Lead Development and Commercialization of TransCon Therapies
In a major strategic move, Ascendis Pharma has joined forces with Teijin Limited to develop and bring innovative therapies to patients in Japan. As part of this partnership, Teijin will receive an exclusive license to furthe...






 

Ascendis Pharma A's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com